Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Muir Russell"'
Autor:
Karin Nelander, Maria Lagerstrom‐Fermer, Carl Amilon, Erik Michaëlsson, Maria Heijer, Magnus Kjaer, Muir Russell, David Han, Eva‐Lotte Lindstedt, Carl Whatling, Li‐Ming Gan, Hans Ericsson
Publikováno v:
Clinical and Translational Science, Vol 14, Iss 3, Pp 812-819 (2021)
We evaluated safety, tolerability, pharmacokinetics (PKs), and pharmacodynamics of AZD4831, a novel oral myeloperoxidase (MPO) inhibitor, in a randomized, single‐blind, placebo‐controlled study, following once‐daily multiple ascending dosing to
Externí odkaz:
https://doaj.org/article/56e9be1d8c7f4c148612b0396fe35f83
Autor:
Eva-Lotte Lindstedt, Carl Amilon, Hans Ericsson, David Han, Maria Heijer, Carl Whatling, Karin Nelander, Li-Ming Gan, Erik Michaëlsson, Maria Lagerström-Fermér, Muir Russell, M Kjaer
Publikováno v:
Clinical and Translational Science, Vol 14, Iss 3, Pp 812-819 (2021)
Clinical and Translational Science
Clinical and Translational Science
We evaluated safety, tolerability, pharmacokinetics (PKs), and pharmacodynamics of AZD4831, a novel oral myeloperoxidase (MPO) inhibitor, in a randomized, single-blind, placebo-controlled study, following once-daily multiple ascending dosing to stead
Autor:
Muir, Russell L.
Publikováno v:
International Journal of Athletic Therapy & Training; Mar2023, Vol. 28 Issue 2, p109-113, 5p
Autor:
John Mo, David J. Keeling, Robert Palmér, Marita Olsson, Christina Lundin, Muir Russell, Rikard Pehrson, Henrik Forsman, David Close, Sara Asimus, Sara Carlert, Muna Albayaty
Publikováno v:
Br J Clin Pharmacol
AIMS: Retinoic acid‐related orphan receptor γ (RORγ), a master regulator of T‐helper 17 (Th17) cell function and differentiation, is an attractive target for treatment of Th17‐driven diseases. This first‐in‐human study aimed to investigat
Autor:
Pablo Forte, Jukka Mäenpää, Robert Palmér, Alexandra Jauhiainen, Susanne Prothon, James Root, Philip Gardiner, Muir Russell, Ligia Chialda, Bengt Larsson, Torbjörn Egelrud, Kristina Stenvall, John Mo
Publikováno v:
Clinical Pharmacology and Therapeutics
Neutrophil serine proteases (NSPs), such as neutrophil elastase (NE), are activated by dipeptidyl peptidase 1 (DPP1) during neutrophil maturation. High NSP levels can be detrimental, particularly in lung tissue, and inhibition of NSPs is therefore an
Autor:
Kyoko Matsuguma, Susanna Eketjäll, Tatsuya Yoshihara, Fumihiko Azuma, Glen Hughes, Kei Sakamoto, Alan R. Kugler, Robert C. Alexander, Naoki Uchida, Muir Russell, Samantha Budd Haeberlein, Shunji Matsuki
Publikováno v:
The Journal of Clinical Pharmacology. 57:1460-1471
Lanabecestat (AZD3293; LY3314814) is an orally active potent inhibitor of human β-secretase 1 in clinical development for the treatment of Alzheimer disease. In this first Japanese clinical study for an Alzheimer disease intervention to include cere
Autor:
Susanna Eketjäll, Muir Russell, Clare A. Balendran, Erik Michaëlsson, Neil Henderson, Glen Hughes, Mark Fidock, Nina Prokoph
Publikováno v:
Journal of immunological methods. 449
Myeloperoxidase (MPO) is predominantly expressed by neutrophils and is an important enzyme used by the immune system for the neutralisation of bacteria and other microorganisms. The strong oxidative activity of MPO has been linked to pro-inflammatory
Autor:
Kei, Sakamoto, Shunji, Matsuki, Kyoko, Matsuguma, Tatsuya, Yoshihara, Naoki, Uchida, Fumihiko, Azuma, Muir, Russell, Glen, Hughes, Samantha Budd, Haeberlein, Robert C, Alexander, Susanna, Eketjäll, Alan R, Kugler
Publikováno v:
Journal of clinical pharmacology. 57(11)
Lanabecestat (AZD3293; LY3314814) is an orally active potent inhibitor of human β-secretase 1 in clinical development for the treatment of Alzheimer disease. In this first Japanese clinical study for an Alzheimer disease intervention to include cere
Autor:
Samantha Budd Haeberlein, Alan R. Kugler, Tina Olsson, Robert C. Alexander, Naidong Ye, Muir Russell, Justine Maltby, Laura B. Rosen, Susanna Eketjäll, Ronald Goldwater, Gvido Cebers, Larry Ereshefsky, David Han
Publikováno v:
Journal of Alzheimer's disease : JAD. 55(3)
AZD3293 (LY3314814) is a promising new potentially disease-modifying BACE1 (β-secretase) inhibitor in Phase III clinical development for the treatment of Alzheimer's disease. Reported here are the first two Phase I studies: (1) a single ascending do
Autor:
Alan R. Kugler, Glen Hughes, Muir Russell, Shunji Matsuki, Robert C. Alexander, Naoki Uchida, Kei Sakamoto, Kyoko Matsuguma, Samantha Budd Haeberlein, Tatsuya Yoshihara, Fumihiko Azuma
Publikováno v:
Alzheimer's & Dementia. 12